pergolide has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clemens, JA; Date, I; Felten, DL; Felten, SY; Steece-Collier, K | 1 |
| Boyce, S; Jenner, P; Marsden, CD | 1 |
| Gsell, W; Lange, KW; Naumann, M; Oestreicher, E; Rausch, WD; Riederer, P | 1 |
| Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E | 1 |
| Cannizzaro, C; Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK | 1 |
| Hirai, K; Ono, S; Tokuda, E | 1 |
| Jenner, P; Kanda, T; Kawai-Uchida, M; Mori, A; Okita, E; Soshiroda, K; Uchida, S | 1 |
3 review(s) available for pergolide and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Age-related decline in the dopaminergic nigrostriatal system: the oxidative hypothesis and protective strategies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Corpus Striatum; Dopamine; Humans; Neurons; Oxidation-Reduction; Parkinson Disease; Pergolide; Substantia Nigra | 1992 |
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Dopamine; Humans; Hydroxydopamines; Injections, Intraperitoneal; Levodopa; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pergolide; Primates; Pyridines; Receptors, Dopamine; Substance Withdrawal Syndrome | 1988 |
Neuroprotection by dopamine agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Bromocriptine; Dopamine Agonists; Humans; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Pergolide | 1994 |
4 other study(ies) available for pergolide and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide | 1995 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index | 2003 |
Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Disease Models, Animal; Dopamine Agonists; Gene Expression; Lipid Peroxidation; Malondialdehyde; Metallothionein; Mice; Mice, Inbred C57BL; Parkinson Disease; Pergolide; RNA, Messenger | 2009 |
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Callithrix; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Female; Indoles; Levodopa; Male; Motor Activity; Pergolide; Purines; Receptor, Adenosine A2A | 2015 |